Reeves, James A.
Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL;
4 papers on CoChatORCID 0000-0001-9690-7341
Most cited papers
- Verified
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 1,260
- Verified
Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 577
- Verified
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer
Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors Research
Cited by 104
- Verified
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
Tolcher, A. W., Reeves, J. A., McKean, M., Chmielowski, B., Beck, J. T., Shaheen, M. F., Somaiah, N., Wilson, M., Spira, A. I., Drabick, J. J., et al. (2021) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCancer-related Molecular Pathways
Cited by 23
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free